Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
NVP-BHG712
Cat No.
CEI-0158
Description
NVP-BHG712 can inhibit c-Raf, c-Src and c-Abl with IC50 of 0.395 uM, 1.266 uM and 1.667 uM.
CAS No.
940310-85-0
Molecular Weight
503.48
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
c-Raf, c-Src, c-Abl
Molecular Formula
C26H20F3N7O
Chemical Name
4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide
Solubility
DMSO 101 mg/mL Water
In vitro
As a small molecular weight kinase inhibitor of the EphB4 kinase, NVP-BHG712, which inhibits EphB4 kinase activity in the low nanomolar range in cellular assays. NVP-BHG712 shows excellent pharmacokinetic properties and potently inhibits EphB4 autophosphorylation in tissues after oral administration. In vivo, NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity in vitro or in cellular assays. NVP-BHG712 can inhibit VEGF induced angiogenesis through inhibiting EphB4, because EphB4 plays an important role in VEGF induced angiogenesis.
In vivo
After oral administration, NVP-BHG712 shows excellent pharmacokinetic properties and potently inhibits EphB4 autophosphorylation in tissues. In vivo, NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity .
Download
Download Datasheet